“急性”与“非急性”:肝硬化失代偿分期的新方向？

摘要/Abstract

摘要： 肝硬化是全球主要的健康负担,临床管理高度依赖精准分期。传统的分期虽不断细化,但其根本目的在于串联起疾病的病理生理、临床表型与预后,从而指导治疗决策。近年来,随着人们对疾病进程认识的深入,有学者提出应进一步将失代偿期划分为急性失代偿期与非急性失代偿期,以期实现更精细的风险分层与管理。然而,基于现有的证据,尤其是从临床普适性、病理生理异质性及实践指导价值的角度审视,这一细分方案尚存在局限性,在我国临床实践中的推广有待验证。

关键词: 肝硬化, Child-Pugh评分, 肝硬化失代偿期, 肝硬化代偿期

董晅, 郑琦. “急性”与“非急性”:肝硬化失代偿分期的新方向？[J]. 肝脏, 2025, 30(12): 1589-1591.

/ 推荐

参考文献

[1] GBD 2023 Causes of Death Collaborators. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023[J]. Lancet, 2025, 406(10513): 1811-1872.
[2] Lu K, Sui J, Yu W, et al. An analysis of the burden of liver cirrhosis: Differences between the global, China, the United States and India[J]. Liver Int, 2024, 44(12): 3183-3203.
[3] Ginés P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors[J]. Hepatology, 1987, 7(1): 122-128.
[4] Planas R, Montoliu S, Ballesté B, et al. Natural history of patients hospitalized for management of cirrhotic ascites[J]. Clin Gastroenterol Hepatol, 2006, 4(11): 1385-1394.
[5] D′Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies[J]. J Hepatol, 2006, 44(1): 217-231.
[6] Premkumar M, Kamath P S, Reiberger T, et al. Recompensation in decompensated cirrhosis[J]. Lancet Gastroenterol Hepatol, 2025, 10(11): 1028-1040.
[7] Reiberger T, Hofer B S. The Baveno Ⅶ concept of cirrhosis recompensation[J]. Dig Liver Dis, 2023, 55(4): 431-441.
[8] 王亚萍杨秀涵, 蔡海奕. 肝硬化再代偿不同分期的临床研究进展[J]. 中华肝脏病杂志, 2025, 33(08): 715-720.
[9] D′Amico G, Morabito A, D′Amico M, et al. New concepts on the clinical course and stratification of compensated and decompensated cirrhosis[J]. Hepatol Int, 2018, 12(Suppl 1): 34-43.
[10] D′Amico G, Morabito A, D′Amico M, et al. Clinical states of cirrhosis and competing risks[J]. J Hepatol, 2018, 68(3): 563-576.
[11] Pugh R N, Murray-Lyon I M, Dawson J L, et al. Transection of the oesophagus for bleeding oesophageal varices[J]. Br J Surg, 1973, 60(8): 646-649.
[12] Malinchoc M, Kamath P S, Gordon F D, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts[J]. Hepatology, 2000, 31(4): 864-871.
[13] Verma N, Kaur P, Garg P, et al. Clinical and pathophysiological characteristics of non-acute decompensation of cirrhosis[J]. J Hepatol, 2025, 83(3): 670-681.
[14] Miyata T, Wu X, Fan X, et al. Differential role of MLKL in alcohol-associated and non-alcohol-associated fatty liver diseases in mice and humans[J]. JCI Insight, 2021, 6(4): e140180.
[15] Liang J, Han T, Gao Y T, et al. The expression of serum M30 and M65 in chronic hepatitis B patients with non-alcoholic fatty liver disease[J]. Eur Rev Med Pharmacol Sci, 2015, 19(21): 4123-4129.
[16] Arvaniti V, D′Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis[J]. Gastroenterology, 2010, 139(4): 1246-1256, 1256.e1-5.
[17] Vucur M, Roderburg C, Kaiser L, et al. Elevated serum levels of mixed lineage kinase domain-like protein predict survival of patients during intensive care unit treatment[J]. Dis Markers, 2018, 1983421.